HomeCompareSCPS vs SBUX

SCPS vs SBUX: Dividend Comparison 2026

SCPS yields 500000.00% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCPS wins by $4.663521010693878e+33M in total portfolio value
10 years
SCPS
SCPS
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full SCPS calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — SCPS vs SBUX

📍 SCPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCPSSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCPS + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCPS pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPS
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SCPS beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPS + SBUX for your $10,000?

SCPS: 50%SBUX: 50%
100% SBUX50/50100% SCPS
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

SCPS
No analyst data
Altman Z
-250.9
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPS buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCPSSBUX
Forward yield500000.00%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$4.663521010693878e+33M$157.5K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$65,840.13
Total dividends collected$4.6634009849658873e+33M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SCPS vs SBUX ($10,000, DRIP)

YearSCPS PortfolioSCPS Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,107$407.21+$50.00MSCPS
2$233,748,371,262$233,694,859,813.08$12,512$626.87+$233748.36MSCPS
3$1,021,074,511,412,696$1,020,824,400,655,446.10$14,366$978.69+$1021074511.40MSCPS
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$16,929$1,557.50+$4168597328794.93MSCPS
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$20,658$2,543.80+$15905475114600664.00MSCPS
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$26,406$4,302.22+$56718938532531060736.00MSCPS
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$35,877$7,622.00+$1.8903180743562385e+23MSCPS
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$52,741$14,352.64+$5.8879981047651824e+26MSCPS
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$85,676$29,243.03+$1.7140642681147225e+30MSCPS
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$157,513$65,840.13+$4.663521010693878e+33MSCPS

SCPS vs SBUX: Complete Analysis 2026

SCPSStock

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Full SCPS Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this SCPS vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPS vs SCHDSCPS vs JEPISCPS vs OSCPS vs KOSCPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.